The Chandler Lab focuses on identifying and understanding disease-related glycoproteins and glycans that influence how illnesses develop and progress. Research places particular emphasis on oral cancer and neuroinflammatory disorders, with the goal of uncovering biological mechanisms that can serve as targets for earlier detection and more effective treatment. The lab integrates glycoproteomics, glycobiology and in vivo disease models to define how glycan-dependent changes affect cellular signaling and disease pathways. By studying these underexplored molecular processes, the program aims to generate insights with strong potential for clinical translation.
research interests
Kevin Chandler’s research uses mass spectrometry to understand how protein modifications influence cell signaling and disease. His work focuses on glycosylation and its role in cancer development, tumor blood vessel formation and response to treatment. His research interests center on defining how N-glycosylation affects vascular endothelial growth factor receptor (VEGFR2) signaling in colorectal cancer and epidermal growth factor receptor (EGFR) signaling in oral squamous cell carcinoma. His studies of sialic acid–related changes in VEGFR2 signaling have helped clarify links between immune and angiogenic pathways. With a background in biochemistry, analytical chemistry and tumor biology, Chandler’s work aims to advance knowledge that can support improved cancer diagnosis and care.